Phase 2b RCT | An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis

An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study – The Lancet (link to abstract – $ for full-text)

News Release: New Treatment for Moderate to Severe Atopic Dermatitis Shows Promising Long-Term Results – Mount Sinai Health System

Commentary: Rocatinlimab Effective for Moderate-to-Severe Atopic Dermatitis – HealthDay

Commentary on Twitter:

Just published in The Lancet: Patients treated w- rocatinlimab, an anti-OX40 antibody, had progressive improvements in atopic dermatitis, which was maintained in most pts after treatment stopped. @EmmaGuttman PI. Details: https://t.co/PpiKsy0ra0 pic.twitter.com/6ghKpsLQsZ

— Mount Sinai Dermatology (@MSHSDerm) December 10, 2022